{
    "eid": "2-s2.0-85150800372",
    "title": "Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing",
    "cover-date": "2023-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anticoagulants",
        "anticoagulation reversal",
        "factor Xa inhibitors",
        "hemostasis",
        "prothrombin complex concentrates"
    ],
    "authors": [
        "Thita Chiasakul",
        "Mark Crowther",
        "Adam Cuker"
    ],
    "citedby-count": 0,
    "ref-count": 58,
    "ref-list": [
        "National trends in ambulatory oral nticoagulant use",
        "Trends in anticoagulant prescribing: a review of local policies in English primary care",
        "Direct-acting oral anticoagulants and their reversal agents-an update",
        "Prothrombin complex concentrates: an update",
        "Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis",
        "Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis",
        "Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants",
        "Reversing rivaroxaban anticoagulation as part of a multimodal hemostatic intervention in a polytrauma animal model",
        "The impact of prothrombin complex concentrates when treating doac-associated bleeding: a review",
        "European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage",
        "Endoscopic iagnosis and Management of Nonvariceal Upper Gastrointestinal Hemorrhage (Nvugih): European Society of Gastrointestinal Endoscopy (Esge) Guideline - Update 2021",
        "Management of bsevere perioperative leeding: guidelines from the European Society of Anaesthesiology: first update 2016",
        "Canadian Stroke Best Practice Recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020",
        "The European Guideline on Management of Major Bleeding and Coagulopathy Following Trauma: Fifth Edition",
        "2020 Acc Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee",
        "American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Optimal Management of Anticoagulation Therapy",
        "2022 Guideline for the Management of Patients with Spontaneous Intracerebral Hemorrhage: A Guideline from the American Heart Association/American Stroke Association",
        "Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel",
        "The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation",
        "Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum",
        "Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban",
        "Comparison of hemostatic outcomes in patients receiving fixed-dose vs. weight-based 4-factor prothrombin complex concentrate",
        "Optimal dosage and administration practices for vitamin K antagonist reversal with 4-factor prothrombin complex concentrate",
        "Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4f-Pcc) for oral anticoagulation reversal",
        "Impact of fixed-dose 4f-Pcc versus weight-based 4f-Pcc for factor Xa inhibitor major bleeding",
        "Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (Prisma-P) 2015 Statement",
        "The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews",
        "The Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses",
        "A Basic Introduction to Fixed-Effect and Random-Effects Models for Meta-Analysis",
        "Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: A Cohort Study",
        "Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study",
        "Efficacy and safety of prothrombin complex concentrate in patients rreated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding",
        "Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4f-Pcc) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages",
        "A Low-dose 4f-Pcc protocol for Doac-associated intracranial hemorrhage",
        "Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage",
        "Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products",
        "High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage",
        "Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage",
        "Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors",
        "Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate",
        "Efficacy of 4-factor prothrombin complex concentrates in factor Xa inhibitor-associated intracranial bleeding",
        "Neurocritical Care Society Pharmacy Study Group. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results from a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates",
        "Comparison of 4-factor Pcc reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage",
        "Andexanet Alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage",
        "A retrospective review of four-factor prothrombin complex concentrate for factor Xa inhibitor-related bleedings",
        "Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate",
        "Four-factor prothrombin complex concentrate for reversal of factor Xa inhibitors versus warfarin in life-threatening bleeding",
        "Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate",
        "Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the Ssc of the Isth",
        "Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase Iiib study",
        "Efficacy and safety of the fixed-dose versus variable-dose of 4-Pcc for vitamin K antagonist reversal: a comprehensive systematic review and meta-analysis",
        "Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors",
        "Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients",
        "Evaluation of 4-factor prothrombin complex concetrate dosing for factor Xa inhibitor reversal",
        "Safety, rfficacy, and cost of four-factor prothrombin complex concentrate (4f-Pcc) in patients with factor Xa inhibitor-related bleeding: a retrospective study",
        "Utilization of 4-factor prothrombin complex concentrate for reversal of oral factor Xa inhibitor-associated acute major bleeding: A Case Series",
        "Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral factor Xa inhibitors"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hamilton",
            "@id": "60031828",
            "affilname": "McMaster University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031828",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Philadelphia",
            "@id": "60023009",
            "affilname": "Penn Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023009",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Meridian HealthComms Ltd",
        "CSL Behring"
    ]
}